Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.
In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500’s 6.9% drop. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.
